<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007158</url>
  </required_header>
  <id_info>
    <org_study_id>GER-EP-23</org_study_id>
    <nct_id>NCT05007158</nct_id>
  </id_info>
  <brief_title>Validation of Procalcitonin as a Biomarker Diagnosing CDI</brief_title>
  <acronym>(DIRT II)</acronym>
  <official_title>A Prospective Case-control Validation of Procalcitonin as a Biomarker Diagnosing Pacemaker and Implantable Cardioverter Defibrillator Pocket Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac device infections (CDI), especially pocket infections, are difficult to be diagnosed.&#xD;
      Device pocket infections are not associated with elevated white blood cell count. CRP is only&#xD;
      assoziated with a low sensitivity. The diagnosis of a local pocket infection is challenging&#xD;
      and relies primarily on the clinical presentation. The prospective DIRT study identified&#xD;
      procalcitonin (PCT) among 14 biomarkers as the most promising biomarker to aid the diagnosis&#xD;
      of pocket infection.&#xD;
&#xD;
      The study aims to validate the proposed PCT cut-off value of 0.05 ng/ml for the diagnosis of&#xD;
      pocket infection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2011</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>diagnostic value of PCT</measure>
    <time_frame>pre-intervention/procedure/surgery. i.e. at the time of CIED explantation. Measurement of PCT as an biomarker revealing the acute infection (like a sepsis marker)</time_frame>
    <description>diagnostic value of PCT in differentiating local pocket infection from infection-free controls and calculated the sensitivity and specificity of the pre-established cut-off value of 0.05 ng/ml</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Implantable Electronic Device Infections</condition>
  <arm_group>
    <arm_group_label>pocket infection</arm_group_label>
    <description>Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIED systemic infection</arm_group_label>
    <description>Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-associated infective endocarditis</arm_group_label>
    <description>Patients with infective endocarditis, diagnosed according to modified Duke criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>procalcitonin blood test</intervention_name>
    <description>blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit</description>
    <arm_group_label>CIED systemic infection</arm_group_label>
    <arm_group_label>Lead-associated infective endocarditis</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>pocket infection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients presenting with cardiac device infection CDI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ device associated infections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  cytostatic or immunomodulating therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

